Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
AACR approaches, along with ASCO abstract titles.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
At least 15 dual-payload ADCs will be discussed.
